Clinical Trial Detail

NCT ID NCT02587650
Title Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors University of California, San Francisco
Indications

melanoma

Therapies

Ceritinib

Capmatinib

Regorafenib

Entrectinib

Age Groups: adult senior

Additional content available in CKB BOOST